19:38 , Apr 27, 2018 |  BC Week In Review  |  Company News

Tonghua gets rights to two insulin products from Adocia

Adocia S.A. (Euronext:ADOC) granted Tonghua Dongbao Pharmaceutical Co. Ltd. (Shanghai:600867) exclusive rights to develop and commercialize BioChaperone Lispro (BioChaperone Ultra fast-acting insulin analog) and BioChaperone insulin combo in China and other undisclosed countries. Adocia will...
06:12 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog

In early June, Adocia S.A. (Euronext:ADOC) began a 3-way crossover Phase II trial to compare single subcutaneous doses of 0.15 U/kg BioChaperone Lispro vs. 0.15 U/kg Fiasp ( faster-acting insulin aspart , NN1218) or 0.15...
00:41 , Feb 3, 2017 |  BC Week In Review  |  Company News

Adocia, Lilly deal

Eli Lilly terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type II diabetes. Lilly had paid $50 million up front for exclusive, worldwide rights to the ultra-fast-acting...
23:13 , Jan 27, 2017 |  BC Extra  |  Company News

Lilly returns diabetes candidate to Adocia

Adocia S.A. (Euronext:ADOC) sank EUR 12.67 (31%) to EUR 27.60 after it said Eli Lilly and Co. (NYSE:LLY) terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type...
07:00 , Aug 26, 2016 |  BC Extra  |  Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

BioChaperone Lispro: Phase Ib data

Top-line data from a double-blind, crossover, German Phase Ib trial in 36 Type I diabetics showed that subcutaneous BioChaperone Lispro U100 given at mealtime significantly reduced blood glucose excursion vs. Humalog insulin lispro over the...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

BioChaperone Lispro: Phase Ib started

Adocia and Eli Lilly began a double-blind, 3-period crossover, German Phase Ib trial to compare 3 single doses of 0.1, 0.2 and 0.4 U/kg BioChaperone Lispro every 1-14 days vs. 1 single dose of 0.2...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

BioChaperone Lispro: Phase I data

A 4-way crossover, double-blind Phase I trial in 26 healthy volunteers under euglycemic clamp showed that 0.2 U/kg doses of subcutaneous BioChaperone Lispro U200 retained the ultra-rapid profile of 0.2 U/kg doses of BioChaperone Lispro...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

BioChaperone Lispro: Phase Ib started

Adocia and Eli Lilly began a double-blind, crossover, German Phase Ib trial to compare continuous subcutaneous BioChaperone Lispro delivered via an insulin pump vs. Humalog insulin lispro for 14 days prior to an individualized standard...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

BioChaperone Lispro: Phase Ib started

Adocia and Eli Lilly began a double-blind, crossover, German Phase Ib trial to compare subcutaneous BioChaperone Lispro on days 1, 2, 13 and 14 before a standardized meal vs. Humalog insulin lispro from Lilly in...